Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Accumulated Expenses (2016 - 2025)

BioCorRx's Accumulated Expenses history spans 9 years, with the latest figure at $317577.0 for Q3 2025.

  • For Q3 2025, Accumulated Expenses changed N/A year-over-year to $317577.0; the TTM value through Sep 2025 reached $317577.0, changed N/A, while the annual FY2021 figure was $983.0, 449.16% up from the prior year.
  • Accumulated Expenses for Q3 2025 was $317577.0 at BioCorRx, up from $147871.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $317577.0 in Q3 2025 and bottomed at $299.0 in Q2 2021.
  • The 3-year median for Accumulated Expenses is $1472.0 (2022), against an average of $78279.0.
  • The largest YoY upside for Accumulated Expenses was 730.56% in 2021 against a maximum downside of 449.16% in 2021.
  • A 3-year view of Accumulated Expenses shows it stood at $983.0 in 2021, then surged by 68.06% to $1652.0 in 2022, then soared by 19123.79% to $317577.0 in 2025.
  • Per Business Quant, the three most recent readings for BICX's Accumulated Expenses are $317577.0 (Q3 2025), $147871.0 (Q2 2025), and $1652.0 (Q2 2022).